Answers are grounded in this paper and cite their sources.
Retrospective analysis compares visual outcomes in idiopathic choroidal neovascularization treatments, indicating similar efficacy.
Purpose: We evaluated the short-term outcomes of intravitreal ranibizumab biosimilar CKD-701 in the treatment of idiopathic choroidal neovascularization (CNV) and compared these outcomes with those achieved using bevacizumab.Methods: We retrospectively reviewed medical records of patients diagnosed with idiopathic CNV who received intravitreal CKD-701 injections (n = 16). Best-corrected visual acuity (BCVA) was assessed at baseline, after a single injection, and at 6 months. Moreover, central retinal thickness (CRT) was compared across these three time points and the proportion of patients achieving complete resolution of retinal edema after a single injection was recorded. Anatomical outcomes in the CKD-701 group were compared with those of patients treated with intravitreal bevacizumab (n = 15).Results: Mean logarithm of the minimum angle of resolution BCVA was 0.20 ± 0.21 at baseline, 0.10 ± 0.11 after one injection, and 0.09 ± 0.14 at 6 months. Mean CRT decreased from 337.8 ± 83.5 μm at baseline to 257.9 ± 18.5 μm after one injection and 263.3 ± 29.9 μm at 6 months (p = 0.001). Complete resolution of retinal fluid after a single injection occurred in 15 eyes (93.8%). Compared to the bevacizumab group, no significant differences in the change in BCVA (p = 1.000) or CRT (p = 1.000) were observed over 6 months or in the proportion of eyes with complete fluid resolution after a single injection (p = 0.600).Conclusions: Intravitreal CKD-701 resulted in substantial anatomical improvement in idiopathic CNV, with outcomes comparable to those observed with bevacizumab. Further well-controlled studies are needed to validate these findings.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: